Advertisement

Digestive Diseases and Sciences

, Volume 58, Issue 10, pp 2963–2969 | Cite as

Prevalence of Corticosteroids Use and Disease Course After Initial Steroid Exposure in Ulcerative Colitis

  • Nabeel Khan
  • Ali Abbas
  • Alice Williamson
  • Luis Balart
Original Article

Abstract

Background

Limited nationwide data currently exists regarding corticosteroid (CS) use and long-term outcome after CS initiation in ulcerative colitis (UC).

Aims

The purpose of this study was to assess CS use prevalence and long-term outcomes after the index CS exposure. Our outcomes of interest were CS use level (reintroduction, dependency, and refractoriness), thiopurine use, and colectomy.

Methods

Nationwide data was obtained from the Veterans Affairs (VA) healthcare system for the period 2001–2011. Patients with UC were included if they had been diagnosed in the VA system and if they had filled CS for the first time during the observation period. A retrospective cohort design and time-to-event survival analysis was used to track outcomes of interest.

Results

A total of 1,038 newly-diagnosed patients with UC were identified. The prevalence of CS use over the observation period was 45 %. Four hundred sixty-four CS users with median follow-up of 3.4 years were included. Among the included patients, 65 % required CS reintroduction, 38 % were classified as CS dependent, and 11 % were classified as CS refractory mostly within 2 years after the index CS course. Respectively, 8.6 and 38 % had colectomy and received thiopurine. Colectomy and thiopurine use rates varied significantly according to CS use level.

Conclusions

Approximately half of newly-diagnosed patients with UC required CS. Among CS users, one third of the patients had a sustained response after the initial CS course while two-thirds required further CS therapy. We observed a trend towards higher than previously reported thiopurine use accompanied by marked reduction in colectomy rates.

Keywords

Corticosteroids Ulcerative colitis Thiopurine Colectomy Veterans Affairs 

Notes

Acknowledgments

This study was funded in full by the Department of Veterans Affairs, Veterans Health Administration, Office of Research & Development Health Services, grant number (VA Project No. 425).

Conflict of interest

None.

References

  1. 1.
    Loftus CG, Loftus EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.PubMedCrossRefGoogle Scholar
  2. 2.
    Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol. 1991;26:1247–1256.PubMedCrossRefGoogle Scholar
  3. 3.
    Kornbluth A, Sachar DB. Gastroenterology PPCotACo. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523 (quiz 524).PubMedCrossRefGoogle Scholar
  4. 4.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.PubMedCrossRefGoogle Scholar
  5. 5.
    Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–599 (quiz 600).PubMedCrossRefGoogle Scholar
  6. 6.
    Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–330.PubMedCrossRefGoogle Scholar
  7. 7.
    Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.PubMedCrossRefGoogle Scholar
  8. 8.
    The National Center for Veterans Analysis and Statistics (NCVAS). Trends in the Utilization of VA Programs and Services. 2012; www.va.gov/vetdata. Accessed 21 April 2012.
  9. 9.
    Khan N, Abbas AM, Almukhtar RM, Khan A. Prevalence and predictors of low bone mineral density in males with ulcerative colitis. J Clin Endocrinol Metab. 2013;98:2368–2375. Google Scholar
  10. 10.
    Garcia-Planella E, Mañosa M, Van Domselaar M, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012;44:206–210.PubMedCrossRefGoogle Scholar
  11. 11.
    Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228–1235.PubMedCrossRefGoogle Scholar
  12. 12.
    Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–550.PubMedCrossRefGoogle Scholar
  13. 13.
    Ha CY, Newberry RD, Stone CD, Ciorba MA. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8:682–687. Google Scholar
  14. 14.
    Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–440.PubMedCrossRefGoogle Scholar
  15. 15.
    Klein RE, Stockford DD. Data on the Socioeconomic Status of Veterans and on VA Program Usage. Office of the Actuary, Veterans Health Administration. 2001; http://www.va.gov/vetdata/docs/SpecialReports/sesprogramnet5-31-01.pdf. Accessed 10 June 2013.
  16. 16.
    Thirumurthi S, Chowdhury R, Richardson P, Abraham NS. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci. 2010;55:2592–2598.PubMedCrossRefGoogle Scholar
  17. 17.
    Morgan RO, Petersen LA, Hasche JC, et al. VHA pharmacy use in veterans with medicare drug coverage. Am J Manag Care. 2009;15:e1–e8.PubMedGoogle Scholar
  18. 18.
    Wolinsky FD, Miller TR, An H, Brezinski PR, Vaughn TE, Rosenthal GE. Dual use of medicare and the Veterans Health Administration: are there adverse health outcomes? BMC Health Serv Res. 2006;6:131.PubMedCrossRefGoogle Scholar
  19. 19.
    U.S. Government Accountability Office Report. Veterans Health Care: Use of VA Services by Medicare-Eligible Veterans. 1994; http://www.gao.gov/products/HEHS-95-13. Accessed 19 February 2013.

Copyright information

© Springer Science+Business Media New York (Outside the USA) 2013

Authors and Affiliations

  • Nabeel Khan
    • 1
    • 2
  • Ali Abbas
    • 1
    • 2
    • 3
  • Alice Williamson
    • 2
  • Luis Balart
    • 1
    • 2
  1. 1.Section of Gastroenterology, Department of Internal MedicineSoutheast Louisiana Veterans Health Care SystemNew OrleansUSA
  2. 2.Section of Gastroenterology and Hepatology, Department of Internal Medicine, Tulane University Health Sciences CenterTulane University School of MedicineNew OrleansUSA
  3. 3.Department of Internal MedicineUniversity of FloridaGainesvilleUSA

Personalised recommendations